Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the
current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I
study now a multi-center phase II-trial was conducted.
Phase:
Phase 2
Details
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology North Eastern Germany Society of Gynaecologic Oncology